F-18 α-Synuclein PET Tracer With Lower Non-Specific Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing central neurological drugs face challenges in crossing the blood-brain barrier and exhibit high non-specific binding, making them unsuitable for reliable imaging of α-synuclein lesions in Parkinson's disease using PET imaging.

Innovation Solution

A method involving sequential steps to prepare a central neurodegeneration imaging agent, F-18-α-syn3, which includes F-18 solution preparation, F-18-α-syn3 solution preparation, and F-18-α-syn3 solution formula steps, reducing logP value and enhancing affinity and specificity, allowing F-18 molecules to bind specifically to misfolded α-synuclein.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If compound 46a is used as a PET imaging agent, then it shows high affinity to α-synuclein fibrils, but it exhibits high non-specific binding due to high lipophilicity

Engineering Contradiction:

Improveaffinity to α-synucleinVSAvoidnon-specific binding

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent modifies the lipophilicity parameter of compound 46a by introducing polar groups (carboxyl, hydroxyl, or amino groups) at specific positions in the molecular structure. This changes the logP value from 4.18 to a lower range, reducing non-specific binding while preserving affinity for α-synuclein fibrils. The chemical structure is adjusted to balance hydrophobic and hydrophilic properties.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If compound 46a is used for imaging, then it binds to α-synuclein with high affinity, but it fails to cross the blood-brain barrier reliably

Engineering Contradiction:

Improvebinding specificityVSAvoidblood-brain barrier penetration

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent adjusts the lipophilicity parameter by introducing polar functional groups that improve blood-brain barrier penetration. The modified compound maintains high affinity for α-synuclein while achieving reliable crossing of the blood-brain barrier, resolving the contradiction between binding specificity and barrier penetration.

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If the logP value is reduced to improve blood-brain barrier crossing, then penetration ability increases, but binding affinity may be compromised

Engineering Contradiction:

Improveblood-brain barrier penetrationVSAvoidbinding affinity

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent carefully modifies the molecular structure by introducing polar groups at specific positions that minimize the impact on binding affinity while maximizing blood-brain barrier penetration. The structural adjustments are designed to maintain the essential interaction sites for α-synuclein binding while improving overall lipophilicity balance.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite molecular structure combining hydrophobic core regions with hydrophilic functional groups. This composite structure allows the molecule to maintain high affinity binding through hydrophobic interactions while the hydrophilic groups facilitate blood-brain barrier crossing, resolving the contradiction between penetration and affinity.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The F-18-α-syn3 agent effectively reduces logP value, demonstrates high affinity and specificity to α-synuclein, and successfully crosses the blood-brain barrier, providing clear imaging of Parkinson's disease lesions with reduced background absorption.

Implementation Method 1

F-18 molecules specifically bind to misfolded α-synuclein to display lesions in images of positron emission tomography (PET)

Methodology Applied

Scientific EffectMolecular recognition:

Implementation Method 2

It is not easy for central neurological drugs to pass through the blood-brain barrier (BBB)... compound 46a manifests the highest affinity to α-synuclein fibrils

Methodology Applied

Scientific EffectPassive diffusion: Diffusion

Data Source

PatentUS20250360233A1Central Neurodegeneration Imaging Agent and Method of Preparing the Same

Publication Date: 2025.11.27 NAT ATOMIC RES INST

AI summary

A central neurodegeneration imaging agent and a method of preparing the same include steps of a reaction between a central nerve positron imaging agent precursor and a marker Fluorine-18 (F-18) and an imaging agent formula. After the labeling process, F-18 molecules specifically bind to misfolded α-synuclein to display lesions in images of positron emission tomography (PET). Therefore, in animal mode brain imaging images, the invention indicates that the F-18-α-syn3 imaging agent achieves an obviously better images of the brains of rotenone-treated mice with Parkinson's disease (PD) than mice not treated with rotenone in experiments.